Mycophenolate mofetil-based immunosuppressive minimization and withdrawal strategies in renal transplantation: Possible risks and benefits

Current Opinion in Nephrology and Hypertension

Volumn 15, Issue SUPPL. 1, 2006, Pages

  Meier Kriesche, Herwig Ulf ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitor sparing; Low toxicity immunosuppression; Mycophenolate mofetil; Renal transplantation; Steroid sparing; Toxicity sparing

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ANEMIA; CANCER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GINGIVITIS; GRAFT FAILURE; GRAFT SURVIVAL; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOMA; NEPHROTOXICITY; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER; TREATMENT WITHDRAWAL; TREMOR; TUMOR; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; CALCINEURIN; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33748053303     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mnh.0000236065.75007.5e     Document Type: Review

References (39)

1. Cameron JI, Whiteside C, Katz J, Devins GM. Differences in quality of life across renal replacement therapies: meta-analytic comparison. Am J Kidney Dis 2000; 35:629-637.
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341:1725-1730.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4:378-383.
4. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4:1289-1295.
5. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940.
6. Nankevell BJ, Borrows RJ, Fung CL-S, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78:557-565.
7. ERA-EDTA Registry. ERA-EDTA Registry 2003 annual report. Amsterdam, the Netherlands: Academic Medical Center; May 2005.
8. US Renal Data System. USRDS 2005 annual data report: atlas of end-stage renal disease in the United States. Bethesda, USA: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
9. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346:580-590.
10. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16:1545-1549.
11. Veenstra DL, Best JH, Hornberger J, et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33:829-839.
12. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80 (Suppl. 2):S254-S264.
13. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397:530-534.
14. Swann PF, Waters TR, Moulton DC, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109-1111.
15. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63:39-47.
16. Meier-Kriesche H-U, Steffen BJ, Hochberg AM, et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75:1341-1346.
17. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69:2405-2409.
18. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80(Suppl. 2):S181-S190.
19. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14:65-81.
20. Birkeland SA, Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation 2003; 76:984-988.
21. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36:2068-2070.
22. Abramovicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16:2234-2240.
23. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13:536-543.
24. Smak Gregoor PJ, van Gelder T, van Besouw NM, et al. Withdrawal of cyclosporine or prednisolone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13:1365-1373.
25. Dudley C, Phanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine A in renal transplant recipients with chronic progressive allograft dysfunction: the 'creeping creatinine' study. Transplantation 2005; 79:466-475.
26. Weir MR, Ward MT, Bahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59:1567-1573.
27. Pascual M, Curtis J, Delmonico FL, et al. A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75:1501-1505.
28. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147:645-657.
29. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68:1865-1874.
30. Squifflet JP, Vanrenterghem Y, van Hooff JP, et al., the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34:1584-1586.
31. Vanrenterghem Y, Lebranchu Y, Hene R, et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70:1352-1359.
32. Woodle ES, Alloway RR, Roy-Chaudhury P, et al. Multivariate analysis of early and late acute rejection risk in 381 renal transplants following early corticosteroid withdrawal. Am J Transplant 2005; 5 (Suppl. 11):242 [Abstract 19].
33. Kaplan B, Meier-Kriesche HU. Mortality risk assessment after renal transplantation. Clin Transpl 2002; 16:131-136.
34. Winkelmayer WC, Weinstein MC, Mittleman MA, et al. Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making 2002; 22:417-430.
35. Chapman JR. Optimising the long-term outcome of renal transplants: opportunities created by sirolimus. Transplant Proc 2003; 35 (3 Suppl.):67S-72S.
36. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5:2496-2503.
37. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17:200-205.
38. Le Meur Y, Buchler M, Lavaud S, et al. Concentration controled versus fixed dose of MMF in kidney transplant recipients: preliminary results of a French multicenter randomized study. Am J Transplant 2005; 5 (Suppl. 11):242 [Abstract 338].
39. Carter S, Taylor D, Levenson R. A question of choice - compliance in medicine taking. A preliminary review. London: Medicines Partnership; 2005.